Recent
price
P/E
ratio
div
yld
3.43%
ROIC.AI
•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Ahead of Gilead (GILD) Q3 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
Earnings Preview: Gilead Sciences (GILD) Q3 Earnings Expected to Decline
Gilead Sciences (GILD) Stock Sinks As Market Gains: Here's Why
3 Absurdly Cheap Stocks That Pay High Dividends
Why Gilead Sciences (GILD) Dipped More Than Broader Market Today
Calls of the Day: Gilead, Berkshire Hathaway and SLB
Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48
Gilead voluntarily withdraws urothelial cancer drug in US
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
This Gilead Sciences Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Gilead Sciences (GILD) Rises As Market Takes a Dip: Key Facts
Gilead's HIV Prevention Treatment Lenacapavir Shows Potential
Hunting For Magnificent Growth Next Year? Check Out These 7 Stocks.
Gilead to Present Late-Breaking Data Highlighting Antiviral Portfolio, Innovative Research Pipeline and HIV Leadership at IDWeek 2024
Gilead Sciences (GILD) Increases Yet Falls Behind Market: What Investors Need to Know
Consider Buying Gilead To Benefit From Its Strong Outlook, Favorable Valuation
GILD Grants Right for HIV PrEP Candidate to Six Generic Companies
Gilead to donate remdesivir for emergency use against Marburg disease in Rwanda
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.